拉帕替尼致肝炎：一例报告。
Lapatinib-induced hepatitis: a case report.
机构信息
Department of Medical Oncology, University Hospital of Patras, 26500 Rio, Patras, Greece.
出版信息
World J Gastroenterol. 2011 May 14;17(18):2349-52. doi: 10.3748/wjg.v17.i18.2349.
Abstract
Lapatinib is an inhibitor of the tyrosine kinases of human epidermal growth factor receptor type 2 (HER2) and epidermal growth factor receptor type 1, with clinical activity in HER2-positive metastatic breast cancer. We present here a 60 year-old patient with metastatic breast cancer who presented with jaundice and increased serum aminotransferase levels and who had been treated with lapatinib for the previous 14 days. Laboratory tests excluded other causes of acute liver injury. Liver biopsy revealed lesions compatible with drug-induced hepatotoxicity. Bilirubin and liver enzymes returned to normal within three months of lapatinib discontinuation. Lapatinib should be included among the causes of drug-induced hepatitis.
摘要
拉帕替尼是一种人表皮生长因子受体 2（HER2）和表皮生长因子受体 1 的酪氨酸激酶抑制剂，在 HER2 阳性转移性乳腺癌中有临床活性。我们在此介绍一位 60 岁的转移性乳腺癌患者，该患者出现黄疸和血清转氨酶水平升高，并且在过去 14 天内接受了拉帕替尼治疗。实验室检查排除了其他急性肝损伤的原因。肝活检显示符合药物性肝毒性的病变。停用拉帕替尼后三个月内胆红素和肝酶恢复正常。拉帕替尼应列入药物性肝炎的病因之一。
相似文献
1
Lapatinib-induced hepatitis: a case report.拉帕替尼致肝炎：一例报告。
World J Gastroenterol. 2011 May 14;17(18):2349-52. doi: 10.3748/wjg.v17.i18.2349.
2
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.前瞻性验证 HLA-DRB1*07:01 等位基因携带作为拉帕替尼诱导肝损伤的预测性风险因素。
J Clin Oncol. 2014 Aug 1;32(22):2296-303. doi: 10.1200/JCO.2013.52.9867. Epub 2014 Mar 31.
3
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.曲妥珠单抗-美坦新偶联物对比卡培他滨加拉帕替尼用于既往治疗的 HER2 阳性晚期乳腺癌患者（EMILIA）：一项随机、开放标签、III 期试验的最终总生存结果的描述性分析。
Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16.
4
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.拉帕替尼：一种人表皮生长因子受体酪氨酸激酶的双重抑制剂。
Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008.
5
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.拉帕替尼单药治疗化疗难治性HER2阳性和HER2阴性晚期或转移性乳腺癌的II期研究。
Ann Oncol. 2008 Jun;19(6):1068-74. doi: 10.1093/annonc/mdm601. Epub 2008 Feb 17.
6
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.来曲唑联合拉帕替尼对比来曲唑联合安慰剂作为绝经后激素受体阳性转移性乳腺癌的一线治疗。
J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.
7
Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.拉帕替尼联合多西他赛和曲妥珠单抗一线治疗 HER2 阳性转移性乳腺癌的最佳耐受剂量。
Ann Oncol. 2013 Aug;24(8):2005-11. doi: 10.1093/annonc/mdt222.
8
[Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].[接受卡培他滨和拉帕替尼治疗的HER-2(+)乳腺癌患者的肝毒性]
Farm Hosp. 2016 Mar 1;40(2):134-6. doi: 10.7399/fh.2016.40.2.9360.
9
Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.曲妥珠单抗治疗 HER2 阳性乳腺癌的心脏毒性meta 分析
Breast Cancer Res Treat. 2017 Dec;166(3):927-936. doi: 10.1007/s10549-017-4460-9. Epub 2017 Aug 19.
10
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.肿瘤浸润淋巴细胞与曲妥珠单抗联合拉帕替尼治疗 HER2 阳性早期乳腺癌的病理完全缓解和无事件生存的相关性：NeoALTTO 试验的二次分析。
JAMA Oncol. 2015 Jul;1(4):448-54. doi: 10.1001/jamaoncol.2015.0830.
引用本文的文献
1
Management of hepatotoxicity of chemotherapy and targeted agents.化疗及靶向药物肝毒性的管理
Am J Cancer Res. 2021 Jul 15;11(7):3461-3474. eCollection 2021.
2
Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient.病例报告：拉帕替尼和长春瑞滨致转移性乳腺癌患者继发硬化性胆管炎。
Thorac Cancer. 2021 Jun;12(12):1912-1916. doi: 10.1111/1759-7714.13986. Epub 2021 May 6.
3
Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 Cells.拉帕替尼激活HepG2细胞中的 Kelch样ECH相关蛋白1-核因子红细胞2相关因子2通路。
Front Pharmacol. 2020 Jun 30;11:944. doi: 10.3389/fphar.2020.00944. eCollection 2020.
4
Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.个体间 CYP3A 活性的差异影响拉帕替尼的生物活化。
Drug Metab Dispos. 2019 Nov;47(11):1257-1269. doi: 10.1124/dmd.119.088823. Epub 2019 Sep 6.
5
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.多西他赛联合曲妥珠单抗和拉帕替尼治疗HER2过表达的淋巴结阴性乳腺癌的初步研究
Clin Breast Cancer. 2016 Apr;16(2):87-94. doi: 10.1016/j.clbc.2015.09.009. Epub 2015 Sep 25.
6
Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI.机制建模揭示了胆汁酸介导的 DILI 中的关键知识空白。
CPT Pharmacometrics Syst Pharmacol. 2014 Jul 9;3(7):e123. doi: 10.1038/psp.2014.21.
7
Liver injury induced by anticancer chemotherapy and radiation therapy.抗癌化疗和放射治疗引起的肝损伤。
Int J Hepatol. 2013;2013:815105. doi: 10.1155/2013/815105. Epub 2013 Jul 17.
本文引用的文献
1
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.药物性肝损伤命名和因果关系评估的标准化：临床研究研讨会总结。
Hepatology. 2010 Aug;52(2):730-42. doi: 10.1002/hep.23696.
2
Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.拉帕替尼：一种小分子表皮生长因子受体和人表皮生长因子受体-2 酪氨酸激酶抑制剂，用于治疗乳腺癌。
Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029.
3
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.单药拉帕替尼用于在含曲妥珠单抗的一线或二线方案治疗后进展的HER2过表达晚期或转移性乳腺癌。
Ann Oncol. 2009 Jun;20(6):1026-31. doi: 10.1093/annonc/mdn759. Epub 2009 Jan 29.
4
Pharmacogenetics in breast cancer therapy.乳腺癌治疗中的药物遗传学
Clin Cancer Res. 2008 Dec 15;14(24):8027-41. doi: 10.1158/1078-0432.CCR-08-0993.
5
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.拉帕替尼作为ErbB2扩增的局部晚期或转移性乳腺癌一线治疗的疗效和安全性。
J Clin Oncol. 2008 Jun 20;26(18):2999-3005. doi: 10.1200/JCO.2007.14.0590. Epub 2008 May 5.
6
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.拉帕替尼用于人表皮生长因子受体2阳性乳腺癌患者脑转移的II期试验。
J Clin Oncol. 2008 Apr 20;26(12):1993-9. doi: 10.1200/JCO.2007.12.3588.
7
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.厄洛替尼毒性的药物基因组学和药代动力学决定因素。
J Clin Oncol. 2008 Mar 1;26(7):1119-27. doi: 10.1200/JCO.2007.13.1128.
8
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.拉帕替尼联合卡培他滨治疗HER2阳性晚期乳腺癌。
N Engl J Med. 2006 Dec 28;355(26):2733-43. doi: 10.1056/NEJMoa064320.
9
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.拉帕替尼（GW572016）是一种可逆性表皮生长因子受体酪氨酸激酶双重抑制剂，在接受过大量治疗的转移性癌患者中进行的I期安全性、药代动力学及临床活性研究。
J Clin Oncol. 2005 Aug 10;23(23):5305-13. doi: 10.1200/JCO.2005.16.584. Epub 2005 Jun 13.
10
Global cancer statistics, 2002.2002年全球癌症统计数据。
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. doi: 10.3322/canjclin.55.2.74.
Zotero 插件